Denise Kettelberger

Ph.D. - Of Counsel

Patent Law

612.349.3014 | kettelberger@ptslaw.com

Dr. Kettelberger is a patent attorney with deep experience in the biosciences and medical device industries. She provides high-level, strategic counsel to companies drawing from her nearly 30 years of experience in IP law.

Dr. Kettleberger’s work for clients, both domestic and international includes:

  • IP procurement and enforcement strategies
  • IP portfolio management
  • Global market-protection strategies
  • Opinions on patentability, freedom-to-operate, clearance, validity and infringement
  • Post issuance proceedings before the Patent Trial and Appeal Board (PTAB)
  • Due diligence opinions and assessment of intellectual property estates
  • Evaluation of new product launches
  • Drafting and counseling on complex IP-related agreements
  • Licensing, acquisitions and divestitures

With advanced degrees in biology and medicine, Dr. Kettelberger primarily counsels clients in the following technology areas:

  • Biotechnology
  • Medical devices
  • Chemicals
  • Small and large molecule pharmaceuticals
  • Plant and animal genetics
  • Peptide modulators
  • Antibody and antibody fragments – therapeutics and screening
  • Genetic profiling
  • Nucleic acid signature systems
  • Hybrid and transgenic plants
  • Biomedical data software interfaces
  • Organic and small molecule therapeutics
  • Nucleoside and nonnucleoside viral inhibitors
  • Tyrosine kinase inhibitors
  • Quinazoline-photocatalytic files
  • Self-cleaning architectural structures
  • Recombinant therapeutic antibodies

US 7,247,782, Genetic Music, Hennings and Kettelberger

Loyola College, BS, Biology, 1975 University of Maryland School of Medicine, MS, 1982 University of Maryland School of Medicine, Ph.D., 1986 Baylor College of Medicine, Post Doctoral Fellow, 1987 – 1988 South Texas College of Law, JD, 1983, Order of the Lytae

Minnesota
U.S Court of Appeals for the 8th Circuit
Commonwealth of Massachusetts
Texas
U.S. District Court, Southern District of Texas
U.S. Court of Appeals for the 5th Circuit
Court of Appeals for the Federal Circuit
U.S. Supreme Court
United States Patent and Trademark Office
American Intellectual Property Law Education Foundation, Board of Trustees
Children’s Law Center of Minnesota, Volunteer Attorney, 2006 – 2013
 American Intellectual Property Law Association – Vice chair, AIPLA Fellows; Special Committee for Legislation; Special Committee for 101

Minnesota State Bar Association

Minnesota Intellectual Property Law Association

  • Responding to USPTO Rejections, AIPLA Bootcamp (2000-2014) and Claim Drafting and Responding to USPTO Rejections, AIPLA Bootcamp (2014-2015)
  • Product Liability – Biologics and Biosimilars, For the Defense (2011), Winner of Burton Award for Legal Achievement, (2012)
  • Amicus Brief for AIPLA, Nuijten v. Dudas, U.S. Supreme Court (2008)
  • New Patent Rules Preliminarily Enjoined on Eve of Effective Date: What’s Next?, Intellectual Property Today,December 2007
  • Potholes in the Road Ahead: Courts Restructuring the Road to Procuring, Marketing, and Enforcing Patents, Nebraska Lawyer, September 2007
  • Supreme Court Dictates Flexible Approach to Obviousness, Intellectual Property Today, June 2007
  • Personalized Medicine: Paradigm Shift in the Pharma Business, Intellectual Asset Management, IP Value in the Life Science Industries Supplement, 2006
  • Amicus Brief on behalf of AIPLA, Lab Corp v. Metabolite, U.S. Supreme Court, 2006
  • Reaching the Summit—Prevailing at the Federal Circuit, IP Value 2005, Intellectual Asset Management, 2005
  • Continuous Capture and Assessment of Intellectual Property, Inside the Minds: Winning Legal Strategies for Biotech Companies, 2005
  • Bill Has Issues All Will Debate—The Patent Reform Act, The National Law Journal, April 29, 2005
  • Patents and the Human Genome Project, Smith GK, Kettelberger DM.  AIPLA Q J. 1994;22(1):27-64. MID:11660522
  • The chicken progesterone receptor A and B isoforms are products of an alternate translation initiation event, Conneely OM, Kettelberger DM, Tsai MJ, Schrader WT, O’Malley BW. J Biol Chem. 1989 Aug 25; 264(24):14062-4. PMID:2760059
  • Promoter specific activating domains of the chicken progesterone receptor, Conneely OM, Kettelberger DM, Tsai M-J, O’MaIley BW.  In: Gene Regulation By Steroid Hormones, Roy AK, Clark J (eds) Springer-Verlag, New York, vol. IV, 220-231.  (1989)
  • Loss of aromatase activity in porcine granulosa cells during spontaneous luteinization in vitro,  Kettelberger DM, Hoover D, Anderson L., In: 19th annual meeting for the Society for the Study of Reproduction; Ithaca, NY; 1986. Abstract 160.
  • “Strategies for Drafting Claims and Patent Specification to Avoid Section 101 Eligibility Issues: Decisions of the USPTO and Federal Circuit,” Stafford Knowledge Webinar, to be presented June 8, 2017 (Kettelberger and Kowalchyk)
  • “Global Patenting – Comparing Patent Systems of Global Innovation Leaders,” PLI Patent Law Institute, April 6-7 (NYC) and April 27-28 (SFO) (2017)
  • “Restoring the Patent System: Countering Supreme Court Attacks on What Can Be Patented,” moderator, Sunstein Kann Murphy & Timbers, Section 101 Symposium (2016)
  • “Biotech Patents and Section 101 Rejections: Meeting Patent Eligibility Requirements Leveraging Recent Decisions and USPTO Guidance to Overcome Rejections,” Strafford Webinar (2016)
  • “Diving into the Science of Biologics and Biosimilars; What Counsel Needs to Know,” ACI Summit on Biosimilars, Munich (2015)
  • “Post-Alice Corporation – Leveraging USPTO Guidance and Recent Decisions to Meet Sect.101 Patent Sect. 101 Rejections Eligibility Requirements,” Strafford Webinar (2015)
  • “Diving into the Science of Biologics and Biosimilars; What Counsel Needs to Know,” ACI Summit on Biosimilars, Munich (2015)
  • “Biotech and Life Science Patent Issues under 35 USC §112, 4th International Conference on Biotechnology and Life Science Patents,” Baltimore (2015)
  • “Biotech Patent Woes – §101,” High Technology Summit (CASRIP), Seattle (2015)
  • “U.S. Biosimilars – The Courts Interpret BCPIA Steps,” Biologics & Biosimilars Conference, Baltimore (2015)
  • “Issues for Life Science Patents – Section 11,” AIPLA Biotech Patent Law Road Show, Boston (2015)
  • “Diving into the Science of Biologics and Biosimilars:  What Counsel Needs to Know to Formulate a Regulatory and Patent Strategy,” ACI’s Summit on U.S. Biosimilars, Munich (2015)
  • “Responding to USPTO Rejections,” AIPLA Bootcamp (2002- 2015) – lecturer
  • “Subject Matter Eligibility in Biotech and Diagnostics,” The Knowledge Group Webinar, Patent Risks – What you Need to Know (2015)
  • “Issues for Life Science Patents – Section 112,” AIPLA Biotech Patent Law Road Show, Boston (2015)
  • “Biosimilars – The US Approach,” IPIC Annual Conference, Vancouver (2012)
  • “Realizing the Promises of Biotechnology in Today’s Food Crops,” Food, Agriculture & Biofuels 2010 National Conference, Minneapolis (2010)
  • “In Re Bilski and International Exercises in Patent Eligible Subject Matter,” MIPLA CLE Stampede, Minneapolis (2010)
  • “Biosimilars  BIONetworkEast,” Winter Meeting, Miami (2010)
  • “Intellectual Property and the Promise of Personalized Medicine,” Life Science Alley, Minneapolis (2010)
  • “Systems Biology: An Introduction to the New Science,” Life Science Alley Expo, Minneapolis (2009)
  • “Written Description and Full Scope Enablement: Drafting a Specification to Support Broad Claims and Avoid Section 112 Rejections,” Michigan Intellectual Property Law Association, Detroit/ Grand Rapids (2009)
  • “Written Description – The New Enablement?” Minnesota Intellectual Property Law Association, Minneapolis (2009)
  • “Inventor Issues: Practice Tips,” AIPLA Annual Meeting, Washington, DC (2009)
  • “Claiming Innovative Diagnostics Post-Bilski,” BIO Intellectual Property Counsel’s Conference (2009)
  • “Biosimilars 2009 AIPLA Special Committee on FDA,” AIPLA MidWinter Meeting, Miami (2009)
  • “Written Description and Enablement: Where’s the Claim Scope?” AIPLA Annual Meeting, Washington, DC (2008)
  • “Maximizing Interactions With USPTO 10th Advanced Forum on Biotech Patents,” ACI, Boston (2008)
  • “A Practical Approach to KSR,” AIPLA Webinar (2008)
  • “Patent Strategies for Uncertain Times: Stick to Basics,” AIPLA 2008 Spring Meeting, Houston (2008)
  • “Patent Reform at the USPTO, Where Are We Now?” 9th Advanced Forum on Biotech Patents, Boston (2007)
  • “Patent Prosecution in the Wake of KSR,” Minnesota Intellectual Property Law Association, Women in IP Law CLE (August 2007)
  • “Licensing Biotechnology Patents,” Center for Advanced Study and Research in Intellectual Property Law (CASRIP), University of Washington School of Law (2006,2007, 2008)
  • “Biotech Patent Woes – §101,” High Technology Summit (CASRIP), Seattle (2015)
  • “U.S. Biosimilars – The Courts Interpret BCPIA Steps,” Biologics & Biosimilars Conference, Baltimore (2015)
  • “Issues for Life Science Patents – Section 11,” AIPLA Biotech Patent Law Road Show, Boston (2015)
  • “Diving into the Science of Biologics and Biosimilars:  What Counsel Needs to Know to Formulate a Regulatory and Patent Strategy,” ACI’s Summit on U.S. Biosimilars, Munich (2015)
  • “Claim drafting and Responding to USPTO Rejections,” AIPLA Bootcamp (2014-2015)
  • “Responding to USPTO Rejections,” AIPLA Bootcamp (2002- 2015)
  • “Subject Matter Eligibility in Biotech and Diagnostics,” The Knowledge Group Webinar, Patent Risks – What you Need to Know (2015)
  • “Issues for Life Science Patents – Section 112,” AIPLA Biotech Patent Law Road Show, Boston (2015)
  • “Biosimilars – The US Approach,” IPIC Annual Conference, Vancouver (2012)
  • “In Re Bilski and International Exercises in Patent Eligible Subject Matter,” MIPLA Stampede, Minneapolis (2010)
  • “Biosimilars,” BIONetworkEast, Winter Meeting, Miami (2010)
  • “Intellectual Property and the Promise of Personalized Medicine,” Life Science Alley, Minneapolis (2010)
  • “Systems Biology: An Introduction to the New Science,” Life Science Alley Expo, Minneapolis (2009)
  • “Written Description and Full Scope Enablement: Drafting a Specification to Support Broad Claims and Avoid Section 112 Rejections,” Michigan Intellectual Property Law Association, Detroit/ Grand Rapids (2009)
  • “Written Description – The New Enablement?” Minnesota Intellectual Property Law Association, Minneapolis (2009)
  • “Inventor Issues: Practice Tips,” AIPLA Annual Meeting, Washington, DC (2009)
  • “Claiming Innovative Diagnostics Post-Bilski,” BIO Intellectual Property Counsel’s Conference (2009)
  • “Biosimilars 2009 AIPLA Special Committee on FDA,” AIPLA MidWinter Meeting, Miami (2009)
  • “Written Description and Enablement: Where’s the Claim Scope?” AIPLA Annual Meeting, Washington, D.C. (2008)
  • “Maximizing Interactions With USPTO,” 10th Advanced Forum on Biotech Patents, ACI, Boston (2008)
  • “A Practical Approach to KSR,” AIPLA Webinar (2008)
  • “Patent Strategies for Uncertain Times: Stick to Basics,” AIPLA 2008 Spring Meeting, Houston (2008)
  • “Patent Reform at the USPTO, Where Are We Now?” 9th Advanced Forum on Biotech Patents, Boston (2007)
  • “Patent Prosecution in the Wake of KSR,” Minnesota Intellectual Property Law Association, Women in IP Law CLE (August 2007)
  • “Licensing Biotechnology Patents,” Center for Advanced Study and Research in Intellectual Property Law (CASRIP), University of Washington School of Law (2006, 2007, 2008)